2019 AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR
2019 年美国神经治疗与修复学会
基本信息
- 批准号:9762479
- 负责人:
- 金额:$ 2.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Brain InjuriesAcute DiseaseAddressAdultAffectAgeAlzheimer&aposs DiseaseAmericanAngelman SyndromeAreaAwardBasic ScienceBiotechnologyBrainBrain DiseasesCareer ChoiceCell TransplantationCell TransplantsClinicalClinical TrialsCollaborationsCreativenessDancingDataDevelopmentDiagnosisDiseaseEducational workshopEmotionalEnsureEventExposure toFacultyFamilyFosteringFoundationsFundingGeneticGoalsHuntington DiseaseIncidenceIndustryInvestigationLeadLocalesMedicalMedical StudentsMethodsMissionNervous System PhysiologyNeuraxisNeurodegenerative DisordersNeurodevelopmental DisorderNeurologicNeurologic DysfunctionsNeuronsNeuropharmacologyOutcome MeasureParkinson DiseasePatientsPlayPopulationPostdoctoral FellowPrivatizationProceduresPublic HealthPublic Health Applications ResearchRecovery of FunctionRefractoryResearchResearch PersonnelRett SyndromeRoleRunningScienceScientistSenior ScientistSilicon DioxideSocial PlanningSocietiesSpinal Muscular AtrophySpinal cord injuryStem cellsStrokeStudentsTechnologyTherapeuticTherapeutic exerciseTissue EngineeringTrainingTraining and EducationTranslatingTranslational ResearchTransplantationTraumatic Brain InjuryTravelUnited StatesUnited States National Institutes of HealthWagesWritingage related neurodegenerationbasecare costscohortcostdisabilitygene therapygraduate studentimprovedindustry partnerinsightmeetingsnervous system disorderneurogenesisneurotechnologynovelnovel therapeuticsnutritionprecision medicineprogramsrelating to nervous systemrepairedresponsesocioeconomicsstem cell therapytherapeutic developmenttooltranslational approachundergraduate student
项目摘要
Neurodegenerative disorders such as Alzheimer's disease (AD), Huntington's disease and Parkinson's disease
(PD), acute disorders such as traumatic brain injury, spinal cord injury, and stroke, and neurodevelopmental
disorders such as Angelman's Syndrome, Rett Syndrome, and Spinal Muscular Atrophy are amongst a
plethora of devastating neurological conditions for which there are little to no treatments. As the incidence of
many of these disorders increase with age, the number of patients with these disorders is expected to
dramatically increase as the US population continues to age. The financial and emotional burden to patients
and their families is indescribable; in addition, the cost of care and lost wages is an enormous financial liability
for the US economy. The American Society for Neural Therapy and Repair (ASNTR) is a society focused on
basic, translational, and clinical aspects of neurological disorders. The ASNTR membership uses cell
transplantation, gene therapy, tissue engineering, neuropharmacology, and other cutting-edge technologies to
study, and treat, such disorders.
The 2019 annual meeting of ASNTR will be held at Sheraton Sand Key, Clearwater Beach, FL. This locale
provides for a very unique and intimate setting which promotes interactions between junior trainees and
accomplished investigators, as well as fostering unique collaborations. The 2019 meeting will be focused on
new directions in neural repair and therapy in the coming decade, and the challenges of translating new
therapies. As such, planned sessions will cover the “Precision Medicine in Neurodegenerative disease”, “When
to intervene in Neurodegenerative disorders”, and “Emerging Neurotechnologies”. A special session (open to
patients) will focus on the current directions and challenges in Parkinson's disease therapeutics. This session
will also include a Dancing with PD session, which has become a popular session in past ASNTR meetings.
Moreover, ASNTR is tremendously committed to trainees. The society encourages trainee participation in the
governance of ASNTR and focuses on the development of trainees. The purpose of this R13 is to garner travel
support for top trainees (selected from submitted abstracts) to offset their costs to attend the 2019 meeting.
Moreover, in 2019 we have several trainee-activities planned. This includes a workshop “Navigating the Role
of Industry Partnerships in Academic Research” with confirmed speakers with expertise in therapeutic
development for stem cell and gene therapy from both Biotechnology Companies running clinical trials as well
as Senior PIs from academic labs focuses on IND-enabling studies. We will also hold a data blitz for trainees
as well as meet-the-editor luncheons. Moreover, we have planned social events, aimed at furthering the
interaction between faculty and trainees. ASNTR has a strong track record of fostering young investigators,
and we aim to continue in this trajectory. Although we always pursue all methods available (i.e. approach the
biotech industry and private foundations) in order to provide travel support for trainees, support from the NIH is
crucial in order for us to continue on our strong training mission.
神经退行性疾病,如阿尔茨海默病(AD)、亨廷顿病和帕金森病
(PD)急性疾病,如创伤性脑损伤、脊髓损伤和中风,以及神经发育
诸如Angelman综合征、Rett综合征和脊髓性肌萎缩症的疾病属于
过多的破坏性神经系统疾病,几乎没有治疗方法。的发生率
这些疾病中的许多随着年龄的增长而增加,预计患有这些疾病的患者数量
随着美国人口的不断老龄化,对患者的经济和情感负担
此外,护理费用和工资损失是一项巨大的财务负担
对美国经济来说。美国神经治疗和修复学会(ASNTR)是一个专注于
神经系统疾病的基础、转化和临床方面。ASNTR成员资格使用小区
移植、基因治疗、组织工程、神经药理学和其他尖端技术,
研究和治疗这些疾病。
2019年ASNTR年会将在佛罗里达州克利尔沃特海滩的喜来登沙礁举行。
提供了一个非常独特和亲密的环境,促进初级学员之间的互动,
有成就的调查人员,以及促进独特的合作。2019年会议将重点关注
未来十年神经修复和治疗的新方向,以及将新的
治疗因此,计划的会议将涵盖“神经退行性疾病的精准医学”,“当
干预神经退行性疾病”和“新兴神经技术”。特别会议(向
患者)将专注于帕金森病治疗的当前方向和挑战。本届会议
还将包括一个与PD会议,这已成为一个流行的会议在过去ASNTR会议跳舞。
此外,ASNTR对受训人员非常重视。协会鼓励受训者参加
ASNTR的治理,并侧重于学员的发展。这个R13的目的是为了获得旅行
支持优秀学员(从提交的摘要中选出),以抵消他们参加2019年会议的费用。
此外,2019年,我们还计划开展多项培训活动。这包括一个研讨会“导航的作用
学术研究中的行业伙伴关系”与确认的扬声器与治疗专业知识
两家生物技术公司也在进行临床试验,
作为来自学术实验室的高级PI,专注于IND使能研究。我们还将为学员举办一场数据闪电战
还有和编辑见面的午餐会此外,我们还计划了社会活动,旨在促进
教师和学员之间的互动。ASNTR在培养年轻调查人员方面拥有良好的记录,
我们的目标是继续沿着这个轨道前进。虽然我们总是追求所有可用的方法(即接近
生物技术行业和私人基金会),以便为学员提供旅行支持,NIH的支持是
这对我们继续执行强大的训练使命至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kyle Fink其他文献
Kyle Fink的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kyle Fink', 18)}}的其他基金
2020 American Society for Neural Therapy and Repair Conference
2020年美国神经治疗与修复学会会议
- 批准号:
10055563 - 财政年份:2020
- 资助金额:
$ 2.5万 - 项目类别:
MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE
MSCS 旨在生产用于治疗亨廷顿病的 BDNF 和基因编辑货物
- 批准号:
10595651 - 财政年份:2017
- 资助金额:
$ 2.5万 - 项目类别:
MSCs engineered to produce Brain-Derived Neurotrophic Factor for the Treatment of Huntington's disease
间充质干细胞经过改造可产生脑源性神经营养因子,用于治疗亨廷顿病
- 批准号:
9362838 - 财政年份:2017
- 资助金额:
$ 2.5万 - 项目类别:
MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE
MSCS 旨在生产用于治疗亨廷顿病的 BDNF 和基因编辑货物
- 批准号:
10443416 - 财政年份:2017
- 资助金额:
$ 2.5万 - 项目类别:
Novel epigenetic targets for silencing the Huntingtons disease mutation
沉默亨廷顿病突变的新表观遗传靶点
- 批准号:
8960294 - 财政年份:2014
- 资助金额:
$ 2.5万 - 项目类别:
Novel epigenetic targets for silencing the Huntingtons disease mutation
沉默亨廷顿病突变的新表观遗传靶点
- 批准号:
8832937 - 财政年份:2014
- 资助金额:
$ 2.5万 - 项目类别:
相似海外基金
Improving Acute Disease Management for Patients with Alzheimer's Disease and Related Dementias
改善阿尔茨海默病和相关痴呆症患者的急性疾病管理
- 批准号:
10712647 - 财政年份:2001
- 资助金额:
$ 2.5万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
6247642 - 财政年份:1997
- 资助金额:
$ 2.5万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
3718999 - 财政年份:
- 资助金额:
$ 2.5万 - 项目类别:
Neurophysiological alterations in multiple sclerosis patients during acute disease acivity
多发性硬化症患者急性疾病活动期间的神经生理学变化
- 批准号:
465668867 - 财政年份:
- 资助金额:
$ 2.5万 - 项目类别:
Research Grants
SIVMAC 1NEF ALLELE: LYMPHOCYTE ACTIVATION & ACUTE DISEASE IN MACAQUE MONKEYS
SIVMAC 1NEF 等位基因:淋巴细胞激活
- 批准号:
3719026 - 财政年份:
- 资助金额:
$ 2.5万 - 项目类别:














{{item.name}}会员




